Do you wish to market your complementary medicines (vitamins, minerals, nutraceutical products, dietary supplements, and herbal products) in the Australian market? Then it is better to realize that the Australian regulatory requirements are different from other countries for such products.
For example, in the United States of America (USA), such products can reach the pharmacy store, supermarket, and retail stores just by filing the GRAS status (Generally Recognized As Safe)… along with, of course, some basic documentation. But it’s a lot easier there.
On the other hand, Therapeutic Goods Administration (TGA) conducts a thorough review and evaluates the products for safety, efficacy, and quality before the products reach the Australian market and consumers.
While other countries may classify these products as
- Nutritional supplements,
- Homeopathic medicines,
- Traditional medicines,
- Ayurvedic medicines, or
- Aromatherapy, in case of certain other products
But, not Australia!
For the Australian agency, TGA, the name is medicines, “Complementary Medicines”
So, what is the process for registering complementary medicines?
How to register Nutraceuticals (vitamins, minerals, nutraceutical products, dietary supplements, or herbal products) in Australia?
Let’s understand how TGA defines complementary medicines.
What are the Complementary Medicines in Australia?
As per the TGA, Complementary Medicine means a therapeutic good consisting wholly or principally of one or more designated active ingredients, each of which has an established identity and traditional use.
The salient points to consider are as follows.
- TGA regulates complementary medicines under the Therapeutic Goods Act (1989).
- These are generally available for use in self-medication by consumers.
- The majority of complementary medicines are indicated for the relief of symptoms of minor, self-limiting conditions, maintaining health and well-being, or the promotion or enhancement of health.
Australian regulatory body TGA has developed the Australian Regulatory Guidelines for Complementary Medicines (ARGCM) to assist sponsors of complementary medicines to meet their legislative obligations.
One can obtain detailed information by visiting the TGA website. https://www.tga.gov.au/complementary-medicines
Need support to register and market your vitamins, minerals, nutraceutical, dietary supplement, herbal products, or any other product in Australia?
Credevo provides complete regulatory services for complementary medicines and pharmaceutical product registration in Australia. Provide your details in the below form and talk to us now.
Regulatory aspects for filing complementary medicine/nutraceuticals in Australia
- The sponsor needs to list or register the complementary medicines on the Australian Register of Therapeutic Goods (ARTG).
- ARTG is a database that includes details of all therapeutic goods that are imported into, supplied in, or exported from Australia.
- Each therapeutic good that gets included in ARTG gets an AUST number based on the risk associated with it. All marketed products must contain the AUST number on their product label along with the sponsor name and address.
- It is a legal requirement that, unless exempted or excluded, all therapeutic goods are included on the ARTG before their Supply to the consumer.
- An applicant shall submit a detailed dossier of information to the TGA for evaluation. This data must establish that the proposed medicine is of appropriate quality, safety, and efficacy for approval and inclusion on the ARTG.
TGA Classification for complementary medicines
Complementary medicines may either be
- Listed or
depending on their ingredients and the therapeutic claims made for the product.
- The therapeutic claims must have evidence. The stronger the claims made, the stronger the evidence must be.
- Australian TGA adopts a risk-based approach for regulating their medicines review.
- Low-risk products are regulated as ‘Listed Medicines’ compared to high-risk products, which need to be evaluated and marked as ‘Registered Medicines’
- Let us understand what parameters are monitored by TGA for listed and registered medicines through this table below.
- Listed medicines are ‘low risk’ medicines.
- It contains certain low-risk ingredients in acceptable amounts permitted for use in listed medicines by the TGA.
- The product must be manufactured by the principles of Good Manufacturing Practice (GMP)
- The manufacturer follows Good Manufacturing Practice (GMP) while manufacturing the product.
- The indications/claims on listed medicines are not subject to pre-market evaluation. However, at the time of Listing, the Act requires that sponsors certify that they hold the evidence to support indications and claims and claims are true, valid, and not misleading.
Assisted Listed Medicines
- Medicines listed in the ARTG through the assessed listed medicines pathway follow self-certification of the safety and quality of the product.
- TGA performs a pre-market assessment of efficacy to support the proposed indications.
- Registered complementary medicines are relatively higher at risk than listed medicines, based on their ingredients or the indications made for the medicine.
- TGA evaluates the registered medicine completely for quality, safety, and efficacy before accepting them on the Australian Register of Therapeutic Goods (ARTG) and marketing.
Based on the product category decided by you, for your product submission to TGA, you have to prepare a comprehensive dossier for regulatory submission.
Are you planning to register & market your Complementary Medicine product in Australia?
Talk to us today. Provide preliminary details below and we will help you achieve a successful registration in Australia. Credevo can be your strategic partner to make a successful submission on time.
You will get a complete overview of the regulatory framework, process overview, and timelines associated with submissions.
To prepare the dossier for TGA submission, one must consider 6 important aspects related to that. There are crucial requirements related to these sections that we have discussed in part II of this series.